A Pharmacoeconomic Model Comparing Two Long-Acting Treatments for Overactive Bladder

Journal of Managed Care Pharmacy
doi 10.18553/jmcp.2002.8.5.343
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Academy of Managed Care Pharmacy

Related search

Where Will the Next Generation of Medical Treatments for Overactive Bladder Syndrome Come From?

International Journal of Urology
Urology
2020English

Two-Year Safety and Efficacy Outcomes for the Treatment of Overactive Bladder Using a Long-Lived Rechargeable Sacral Neuromodulation System

Neurourology and Urodynamics
NeurologyUrology
2020English

Mirabegron: A Beta-3 Agonist for Overactive Bladder

The Consultant Pharmacist
2014English

Refractory Overactive Bladder: A Common Problem?

International Urogynecology Journal
GynecologyUrologyObstetrics
2015English

Botulinum Toxin a for the Treatment of Overactive Bladder

Toxins
MutagenesisToxicologyHealth
2016English

Stepwise Treatment for Overactive Bladder Is Prudent

Canadian Urological Association Journal
Urology
2017English

Management of Overactive Bladder

2018English

Sacral Neuromodulation for Treatment of Overactive Bladder: A Review

Revista de Medicina
2018English

OnabotulinumtoxinA for the Treatment of Overactive Bladder

Research and Reports in Urology
Urology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy